Northeast Georgia Medical Center - Gainesville

The Northeast Georgia Medical Center is accredited by the Commission on Cancer of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program. The Northeast Georgia Medical Center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers. The center is also accredited by the American College of Radiology (ACR). The Northeast Georgia Medical Center consists of 46 physicians across two locations. The center has board-certified physician specialists and clinical oncology professionals that provide an array of programs and services to meet the needs of cancer patients and their families. State-of-the-art radiation therapy, chemotherapy and biologic and hormone therapies are available treatment options as well as innovative techniques such as prostate seed implant therapy and sentinel node biopsy. The center provides approximately 45-50 ongoing cancer clinical trials, ensuring that patients throughout northeast Georgia have access to the latest research advances in the diagnosis and treatment of cancer. The center has a new service, Patient Navigation, which provides assistance to patients as they navigate the complex healthcare system.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Cancer Type: Brain Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma
Cancer Type: Uterine Cancer

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients With Glioblastoma Multiforme
Cancer Type: Brain Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Cancer Type: Cervical Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Cancer Type: Melanoma
Study Coordinator: Trena Davis BSN, RN, CRCC


A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Cancer Type: Endometrial Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type: Unknown Primary

Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
Cancer Type: Endometrial Cancer

Phase II Randomized Study of Whole-Brain Radiotherapy With Versus Without Lapatinib Ditosylate in Patients With Brain Metastasis From HER2-Positive Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Cancer Type: Ovarian Cancer

Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal
Cancer Type: Ovarian Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC


Phase III Randomized Study of Adjuvant Gemcitabine Hydrochloride With Versus Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With Versus Without Chemoradiotherapy With Either Capecitabine or Fluorouracil in Patients With Resected
Cancer Type: Pancreatic Cancer
Study Coordinator: Trena Davis BSN, RN, CCRC - (770) 219-8822


Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck
Cancer Type: Head and Neck Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - (770) 219-8822


Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Cancer Type: Cervical Cancer

Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - (770) 219-8822


Phase III Randomized Study of Diet and Physical Activity Modification Versus Usual Care in Patients With Previously Treated Stage II, III, or IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC


Phase III Randomized Study of Methotrexate Versus Dactinomycin in Patients With Low-Risk Gestational Trophoblastic Neoplasia
Cancer Type: Unknown Primary

Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy
Cancer Type: Kidney Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822